URGN stock stays tied to UroGen Pharma's pipeline
UroGen Pharma Ltd. (URGN) continues to focus on its kidney and urology pipeline, with its stock performance directly linked to clinical progress and regulatory milestones. With no new catalysts, investors are primarily tracking development execution, commercial uptake of treatments like Jelmyto, and company communications. The Nasdaq listing keeps the biopharmaceutical company on the watchlist for small-cap biotech investors.
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar
UroGen Pharma (URGN) stock appears overvalued despite strong 257% returns over the past three years. Its P/S ratio of 13.2x exceeds both the biotech industry and tailored fair estimates, suggesting investors are paying a premium. While future revenue growth from cancer treatments could support current valuations, ongoing development and funding needs present risks, leading to differing community views on its potential.
URGN - UroGen Pharma Ltd Latest SEC Filings
This article provides the latest SEC filings information for UroGen Pharma Ltd (URGN), including a snapshot of its financial performance, key statistical data, and market metrics. It details the company's valuation, profitability, stock performance, and institutional ownership, offering a comprehensive overview for investors.
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar
UroGen Pharma's stock has seen significant gains, but current market multiples suggest it is overvalued compared to the broader biotech industry and tailored peers. The company's P/S ratio of 13.2x is above the biotech average of 12.4x, and its tailored fair P/S estimate of 11.9x, indicating investors are paying a premium. The article highlights both bull and bear cases, focusing on potential revenue growth from bladder cancer treatments versus concerns about ongoing development costs and funding risks.
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar
UroGen Pharma (URGN) stock has seen significant gains, returning 256.6% over three years and 192.7% in the last year, but is currently screening as overvalued according to Simply Wall St's valuation checks, which assign it a score of 2 out of 6. The company's P/S ratio of 13.2x is higher than the biotech industry average and its tailored fair P/S estimate, suggesting a premium. While future revenue growth from bladder cancer treatments could support the valuation, ongoing development costs and funding needs pose risks, leading to sharply divided opinions among community camps regarding its true value.
Price to book forward of UroGen Pharma Ltd. – NASDAQ:URGN
This article focuses on the "Price to book forward" financial metric for UroGen Pharma Ltd. (NASDAQ: URGN), accessible through TradingView's platform. It indicates that the market was closed at the time of the data retrieval, with no trades occurring. The content primarily serves as a placeholder or a dedicated section within a larger financial data platform.
(URGN) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Urogen Pharma Ltd. (NASDAQ: URGN), highlighting strong positive sentiment across all time horizons and identifying no significant resistance levels above its current price. It presents three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis for support and resistance levels. The analysis aims to offer a "liquidity pulse" for institutional tactics, with key findings supporting an overweight bias for the stock.
Price to book forward of UroGen Pharma Ltd. – SWB:UR8
The article presents the "Price to book forward" financial data for UroGen Pharma Ltd. (SWB:UR8) on the Stuttgart Stock Exchange. The data is part of the company's financials, alongside an overview, news, community insights, forecasts, seasonals, and ETFs. The article itself does not provide specific numerical values for the price to book forward, only indicating the section where this information would be displayed.
Price to sales forward of UroGen Pharma Ltd. – SWB:UR8
The article "Price to sales forward of UroGen Pharma Ltd. – SWB:UR8" is a placeholder or an incomplete page from TradingView. It displays basic market information for UroGen Pharma Ltd. (SWB:UR8) on the Stuttgart Stock Exchange, stating that the market is closed with no trades. The majority of the content consists of navigation links and standard TradingView footer information rather than specific financial data or analysis.
Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN
This article provides access to the "Price to earnings forward" data for UroGen Pharma Ltd. (URGN) on the TradingView platform. It indicates the market for URGN was closed at the time of viewing, with no trades, and points users to where they can find financial information for the company. The content primarily highlights the availability of this specific financial metric and company details within the TradingView ecosystem.
Price to book forward of UroGen Pharma Ltd. – BOATS:URGN
This article provides the "Price to book forward" for UroGen Pharma Ltd. (URGN) traded on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point presented on TradingView, indicating that specific value details would be available within the platform. The provided content is largely navigational and descriptive of the TradingView platform rather than detailed financial analysis.
Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN
The article discusses the enterprise value to EBIT forward for UroGen Pharma Ltd., traded under the ticker NASDAQ: URGN. It is presented in the context of financial data available on TradingView, covering various financial metrics and tools for analysis. The content itself provides little specific detail but serves as a header within a financial data platform.
Enterprise value to EBITDA forward of UroGen Pharma Ltd. – BOATS:URGN
The article focuses on the enterprise value to EBITDA forward for UroGen Pharma Ltd. (URGN). It appears to be a financial data point presented on the TradingView platform, with information provided by various financial data services. The data is available under the company's financial overview on TradingView.
URGN Forecast — Price Target — Prediction for 2027
UroGen Pharma Ltd. (URGN) stock has a strong buy rating according to analysts, with a current price of $34.54 USD and a 151.20% increase over the last year. Analysts have provided future price estimates ranging from a maximum of $45.00 USD to a minimum of $18.00 USD. The company is expected to release its next earnings report on August 6, 2026, and does not pay dividends.
UroGen Pharma (URGN) CMO sells 10,000 shares in planned open-market trade
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 Ordinary Shares in an open-market transaction on June 22, 2026, at a weighted average price of $35.01 per share. The sale was conducted under a Rule 10b5-1(c) trading plan adopted on August 15, 2025. Following this transaction, Schoenberg directly holds 129,763 Ordinary Shares in the company.
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com
This article announces the filing of Form 4 for Urogen Pharma Ltd on June 24, 2026, as reported by Investing.com. It is a brief, stock market-related news item providing a direct update on a company filing. The article also includes various stock market data, indices, and financial news headlines from Investing.com.
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com
This article from Investing.com reports the filing of a Form 4 by Urogen Pharma Ltd on June 24. It provides no further details about the content of the Form 4 but lists the company's stock symbol URGN along with its recent price performance. The piece is brief and primarily serves as an announcement for the regulatory filing.
UroGen Pharma (URGN) director awarded 8,000 RSUs and 10,000 options
UroGen Pharma director James A. Robinson Jr. received 8,000 restricted stock units (RSUs) and options for 10,000 ordinary shares on June 22, 2026. The stock options have an exercise price of $34.99 and expire on June 22, 2036. Both awards vest in equal quarterly installments over one year, contingent on his continued board service, representing routine director compensation rather than open-market trades.
UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike
UroGen Pharma Ltd. director Stuart Holden was granted 20,000 stock options with an exercise price of $34.99 per share, expiring on June 22, 2036. The options will vest in equal quarterly installments over one year, contingent on his continuous service. This transaction was reported via a Form 4 filing, indicating an award for compensation rather than an open-market purchase.
UroGen Pharma (URGN) director receives new RSUs and stock option grant
UroGen Pharma director Daniel George Wildman received new equity awards, including 8,000 restricted stock units and stock options for 10,000 ordinary shares at an exercise price of $34.99 per share. Both RSUs and stock options will vest in equal quarterly installments over one year, contingent on his continuous service to the company. These grants were officially reported in a Form 4 SEC filing on June 24, 2026, and represent a form of long-term equity compensation, not open-market transactions.
UroGen Pharma (URGN) awards director RSUs and stock options
UroGen Pharma Ltd. has granted new equity awards to director Cynthia M. Butitta, consisting of 8,000 restricted stock units (RSUs) and stock options for 10,000 ordinary shares with an exercise price of $34.99 per share. Both awards vest in equal quarterly installments over one year, tying her compensation to the company's long-term performance and continued service. This Form 4 filing reflects compensation grants rather than open-market transactions.
Director at UroGen Pharma (NASDAQ: URGN) granted RSUs and stock options
UroGen Pharma director Leana Wen was granted 8,000 restricted stock units (RSUs) and 10,000 stock options, with an exercise price of $34.99 per share. These equity awards will vest in equal quarterly installments over one year, contingent on her continued service. The transaction, reported in a Form 4 SEC filing, represents compensation and not open-market trading.
[Form 4] UroGen Pharma Ltd. Insider Trading Activity
A Form 4 filing for UroGen Pharma Ltd. reports that director Arie Belldegrun was granted 20,000 stock options at an exercise price of $34.99 per share, expiring in 2036. These options will vest in equal quarterly installments over one year, contingent on his continuous service. After this transaction, Belldegrun holds 20,000 derivative securities directly.
UroGen Pharma (NASDAQ: URGN) OKs new articles and equity plan share increase
UroGen Pharma shareholders approved several key proposals at their 2026 Annual Meeting, including amended and restated Articles of Association to align shareholder proposal eligibility with Israeli law. They also sanctioned a Compensation Policy Amendment and increased authorized shares under the 2017 Equity Incentive Plan by 1,000,000. Additionally, shareholders elected seven director nominees, provided advisory approval for executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor.
UroGen shareholders approve director insurance amendment and 2017 Plan increase
UroGen shareholders have approved an amendment to the company's director and officer insurance policy and an increase of 1,000,000 shares under the 2017 Equity Incentive Plan. These company-wide governance actions were approved at the Annual Meeting, as detailed in an SEC filing from June 23, 2026. The Compensation Policy Amendment relates to directors' and officers' insurance.
UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K
UroGen Pharma Ltd. filed a Form 144 notice disclosing the sale of 10,000 shares of common stock, which originated from a stock option exercise on January 27, 2023. The sale occurred on May 8, 2026, generating aggregate proceeds of $300,048.00. RBC Capital Markets LLC handled the transaction on NASDAQ.
Form 144 UroGen Pharma Ltd. For: 22 June By Investing.com
This article from Investing.com announces a Form 144 filing for UroGen Pharma Ltd., specifically for June 22. It presents various financial market data and trading information but offers no further details about the Form 144 itself.
UroGen Pharma Stock - Saturday overview of strategy and pipeline
This article provides an overview of UroGen Pharma's long-term strategy and pipeline, focusing on its urology-focused therapies and proprietary RTGel technology. The company aims to develop and commercialize treatments for urologic cancers with high unmet needs, utilizing therapies that can be administered in outpatient settings. The article also touches upon the company's business model and where its stock trades.
(URGN) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Urogen Pharma Ltd. (NASDAQ: URGN), highlighting strong positive sentiment across all time horizons and identifying compelling upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss parameters, tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Urogen Pharma stock hits 52-week high at 32.5 USD By Investing.com
Urogen Pharma (URGN) stock reached a 52-week high of $32.50 USD, now trading at $33.10 USD with a market capitalization of $1.56 billion. This surge reflects strong investor confidence and a 141% increase over the past year. The company recently settled patent litigation with Teva Pharmaceuticals and reported positive data from its Phase 3 ENVISION and UTOPIA trials, with analysts reaffirming Buy and Outperform ratings.
Urogen Pharma stock hits 52-week high at 32.5 USD
Urogen Pharma's stock has reached a new 52-week high of $32.5 USD, currently trading at $33.1 USD with a market capitalization of $1.56 billion. This significant increase of 141% over the past year reflects strong investor confidence and growth in the pharmaceutical sector. The company recently announced a patent litigation settlement with Teva Pharmaceuticals for JELMYTO and reported positive durability data from its Phase 3 ENVISION and UTOPIA trials for ZUSDURI and UGN-103, respectively, leading to reaffirmations of Buy and Outperform ratings from analysts.
Why UroGen Pharma (URGN) Is Up 17.2% After Teva Patent Settlement And Zusduri Sales Surge
UroGen Pharma's stock rose 17.2% following a patent settlement with Teva Pharmaceuticals regarding Jelmyto, which delays generic entry until September 2030. This development, coupled with strong first-quarter sales for its new therapy, Zusduri, clarifies the company's revenue-risk profile and product concentration. The article also discusses UroGen's financial projections, emphasizing the need for rapid Zusduri growth to offset losses and the extended patent protection for its pipeline candidate UGN 103.
Why UroGen Pharma (URGN) Is Up 17.2% After Teva Patent Settlement And Zusduri Sales Surge
UroGen Pharma's stock rose 17.2% following a patent settlement with Teva Pharmaceuticals regarding Jelmyto, granting Teva a license for a generic version starting September 2030. This settlement, combined with strong first-quarter sales for UroGen's new therapy, Zusduri, clarifies the company's future competitive landscape and revenue-risk profile. Investors are now evaluating whether Zusduri's rapid growth can offset potential losses and bridge the company to future profitability.
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
TD Cowen has reiterated its "Buy" rating on UroGen Pharma Ltd (URGN.US), maintaining a target price of $35. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 5,222 ordinary shares for $142,560 to cover withholding taxes related to the settlement of restricted stock units. This transaction occurred after the company's shares saw a significant 288% increase over the past year. Schoenberg still holds 139,763 shares, and the company has recently settled a patent dispute for its Jelmyto product and released positive data from clinical trials for ZUSDURI and UGN-103.
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 5,222 ordinary shares for $142,560 to cover withholding tax obligations after acquiring 10,000 shares through restricted stock unit settlement. Despite the sale, Schoenberg still holds 139,763 shares. This transaction follows a significant 288% increase in UroGen's stock price over the past year and comes amidst positive news regarding a patent settlement and promising clinical trial results for the company's bladder cancer treatments.
UroGen Pharma Ltd stock (IL0011408896): Focus on urology pipeline after recent clinical updates
UroGen Pharma Ltd is attracting investor attention due to recent clinical and regulatory updates for its urology-focused pipeline, targeting hard-to-treat urinary tract cancers. The company's strategy centers on proprietary drug delivery technology to enhance therapeutic exposure in the urinary tract. UroGen Pharma's focus on niche uro-oncology positions it as a key player for investors interested in specialized oncology markets, particularly within the US healthcare system.
UroGen Pharma (URGN) CMO nets shares as RSUs vest and 5,222 sold for tax
UroGen Pharma's Chief Medical Officer, Mark Schoenberg, exercised 10,000 Restricted Stock Units (RSUs) on June 8, 2026, converting them into ordinary shares. Concurrently, 5,222 ordinary shares were sold at $27.30 each to cover tax obligations related to this RSU settlement. Following these transactions, Schoenberg directly holds 139,763 ordinary shares of the company.
Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144
Mark Schoeberg, an insider at UroGen Pharma Ltd., reported selling 10,000 ordinary shares of the company on May 8, 2026, for a value of $300,048.00. The filing also noted the issuance of 30,000 ordinary shares to Schoeberg upon the vesting of RSUs on June 8, 2023, without additional consideration. This transaction is considered a routine Form 144 sale by an insider and its impact is assessed as neutral.
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story
UroGen Pharma (URGN) recently resolved patent litigation with Teva Pharmaceuticals regarding its drug Jelmyto, setting a generic entry date for September 2030. This agreement clarifies the drug's intellectual property runway and, along with a new $250 million term loan, aims to reduce legal uncertainty and bolster liquidity. The company's investment narrative now focuses on scaling ZUSDURI and UGN 103 uptake to offset operating losses, with a projected revenue of $536 million and earnings of $173.1 million by 2029.
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story
UroGen Pharma (URGN) has settled its U.S. patent litigation with Teva Pharmaceuticals regarding Jelmyto, allowing Teva to sell a generic version from September 15, 2030. This agreement provides clarity on future competition for UroGen's key urothelial cancer therapy and reduces legal uncertainty. While the 2030 generic entry date does not significantly alter UroGen's near-term focus on ZUSDURI uptake and managing ongoing operating losses, it, along with a new $250 million term loan, frames the company's next few years as a test of its ability to scale new products and reduce reliance on external capital.
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth
UROGEN PHARMA LTD (NASDAQ:URGN) has flawlessly passed the Minervini Trend Template, indicating it's in a strong and sustainable uptrend, and also boasts a High Growth Momentum (HGM) rating of at least 4. This combination signifies that the stock not only shows strong technical trends but is also backed by accelerating business fundamentals including significant earnings and revenue growth. While the technical and fundamental analysis is strong, the report notes that the stock's recent price movement has been volatile and suggests waiting for a period of consolidation before a low-risk entry.
Assessing UroGen Pharma (URGN) Valuation After Jelmyto Patent Settlement With Teva
UroGen Pharma's recent patent settlement with Teva for Jelmyto has brought its valuation into focus, with the stock currently trading at $26.85. Despite a fair value estimate of $36.11, implying a 25.6% undervaluation, the company faces challenges in narrowing losses and managing high operating expenses. The article highlights both the potential upside from minimally invasive therapies and market penetration, and the risks associated with execution and financial performance.
(URGN) Movement as an Input in Quant Signal Sets
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies an exceptional risk-reward setup with a potential 19.1% gain and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes specific entry, target, and stop-loss levels across various time horizons.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 21 new employees. These RSUs are related to their employment with UroGen and fall under Nasdaq Listing Rule 5635(c)(4). The grants are intended to support the commercialization of UroGen's approved products, JELMYTO® and ZUSDURI™, and the continued development of its pipeline.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. has announced inducement restricted stock units (RSUs) to 21 new employees, supporting the commercialization of JELMYTO® and ZUSDURITM and the development of their pipeline. Up to 102,700 ordinary shares are issuable upon vesting over three years, subject to continued employment. These grants serve as a material inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
21 new UroGen staff get stock units to back cancer drugs
UroGen Pharma has granted up to 102,700 inducement Restricted Stock Units (RSUs) to 21 new employees, vesting equally over three years. These new hires will support the commercialization of JELMYTO and ZUSDURI, the company's approved products, and the development of its pipeline. The grants align with Nasdaq Listing Rule 5635(c)(4) and are intended to incentivize employees to contribute to UroGen's growth in urothelial and specialty cancer treatments.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 21 new employees, totaling up to 102,700 ordinary shares. These grants are intended to support the commercialization of their approved products, JELMYTO and ZUSDURI, and the ongoing development of their pipeline. The RSUs will vest over three years, subject to continued employment, and were issued under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 21 new employees in connection with their employment. These RSUs, totaling up to 102,700 ordinary shares, will vest over three years and are intended to support the commercialization of JELMYTO® and ZUSDURI™, as well as the company's pipeline development. The grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.
Oppenheimer reiterates Outperform on UroGen Pharma stock after Teva settlement
Oppenheimer has reiterated an Outperform rating and $40 price target for UroGen Pharma (NASDAQ:URGN) following a settlement with Teva regarding its Jelmyto product, which protects market exclusivity until 2031. The company has shown significant returns and strong analyst consensus, with its new drug Zusduri identified as a major growth driver due to its large market opportunity and strong early launch progress. Recent Q1 2026 earnings beat expectations, and positive Phase 3 trial results for ZUSDURI and UGN-103 further support its promising outlook.
